FLUKE
Kimball Electronics
Tolomatic
Industrial Scientific
AHEAD
roboception
FLUKE
Kimball Electronics
Tolomatic
Industrial Scientific
AHEAD
roboception
By Swetha Sankar | Tue Jul 1 2025 | 2 min read

The EU In Vitro Diagnostic Medical Devices Regulation (IVDR 2017/746) isn’t just an upgrade from the IVDD—it’s a complete overhaul. Enforced since May 26, 2022, the IVDR imposes strict rules on the classification, conformity assessment, and performance evaluation of IVDs in the EU market.

If you manufacture, import, distribute, or place IVD devices in Europe, this regulation applies to you.

What Is the EU IVDR?

The IVDR is a legally binding regulation that governs in vitro diagnostic medical devices—products used to examine specimens derived from the human body (e.g., blood, saliva, tissue) to provide information on health status, diseases, or predispositions.

It replaces the In Vitro Diagnostic Directive (IVDD 98/79/EC) and brings IVDs under a centralized, high-standard regulatory framework. Unlike a directive, the IVDR applies directly across all EU member states, leaving no room for national variation.

Scope and Classification: A Risk-Based Approach

Under the IVDR, devices are classified into four risk classes:

  • Class A (low risk – e.g., lab instruments)
  • Class B
  • Class C
  • Class D (high risk – e.g., HIV, Hepatitis, blood grouping)

Most devices under IVDD were self-certified. Under IVDR, approximately 80–90% now require Notified Body involvement.

> Classification is based on risk to individuals and public health, not just device function.

Performance Evaluation Requirements

The IVDR mandates robust performance evaluation for all IVDs. This includes:

  1. Scientific Validity – evidence linking the analyte to the clinical condition.
  2. Analytical Performance – accuracy, precision, sensitivity, specificity.
  3. Clinical Performance – ability to yield clinically meaningful results.

Manufacturers must document this in a Performance Evaluation Report (PER), updated throughout the device lifecycle.

##CE Marking and Conformity Assessment

Conformity assessment under IVDR depends on the classification:

  • Class A (non-sterile): Self-certification
  • Class A (sterile), B, C, D: Require a Notified Body audit

Once compliant, the manufacturer may affix the CE mark, but the requirements to get there are now much stricter.

Documentation: The Technical File and GSPRs

Manufacturers must build a technical documentation file showing conformity with the General Safety and Performance Requirements (GSPRs) in Annex I of the IVDR.

Key inclusions:

  • Device description and specifications
  • Risk management strategy
  • Performance evaluation plan
  • Labeling and instructions for use
  • UDI assignment and traceability plan

Post-Market Surveillance (PMS) & Vigilance

IVDR requires a proactive PMS system, not a reactive one.

  • Class B–D devices must maintain a Periodic Safety Update Report (PSUR)
  • Vigilance reporting timelines are accelerated (15 days for serious incidents)

Manufacturers must continuously collect and analyze post-market data to update the benefit-risk profile of the device.

Economic Operators and Their Roles

Like MDR, IVDR defines four economic operators:

  1. Manufacturer
  2. Authorized Representative
  3. Importer
  4. Distributor

Each has distinct responsibilities, including:

  • Ensuring documentation availability
  • Reporting complaints or non-conformities
  • Verifying CE marking and labeling language

> Manufacturers outside the EU must appoint an Authorized Representative within the EU.

EUDAMED and UDI

The IVDR mandates the registration of:

  • Devices
  • Economic operators
  • Clinical performance studies

…in EUDAMED, the EU’s central regulatory database.

In addition, every IVD must be assigned a UDI (Unique Device Identifier) to ensure traceability throughout its lifecycle.

IVDR Transition Deadlines (As of 2025)

Due to capacity issues among Notified Bodies and industry readiness, the EU has extended IVDR transition periods:

  • Class D: Until May 26, 2025
  • Class C: Until May 26, 2026
  • Class B and Class A (sterile): Until May 26, 2027

> Only applies to legacy devices with valid IVDD certificates and no significant changes.

How Acquis Helps You Meet IVDR Compliance

Acquis automates and streamlines IVD regulatory compliance with features like:

  • Digital GSPR alignment tools
  • Supplier collaboration for substance disclosure
  • Performance evaluation traceability
  • UDI and EUDAMED registration support
  • PSUR and vigilance reporting automation
  • Compliance workflows for economic operators

Whether you're Class A or Class D, Acquis helps you reduce compliance risk and accelerate CE marking under the IVDR framework.

Request a demo to align your team with EU IVDR today.

Topics

Speak to Our Compliance Experts

Questions about compliance, partnerships, or support? We're here to help.

Share

EU IVDR Compliance: Everything IVD Manufacturers Must Know

IVDR (Regulation EU 2017/746) replaces the IVDD (Directive 98/79/EC) and became fully applicable across the EU/EEA in May 2022. It significantly upgrades risk-based classification, Notified Body oversight (covering ~80–90% of devices), mandatory clinical evidence, UDI requirements, PRRC roles, and mandatory registration in EUDAMED
IVDR applies to all IVD device classes (A–D), with most requiring Notified Body certification (only non-sterile Class A can self-certify). Manufacturers must maintain ISO 13485-based QMS, appoint a Person Responsible for Regulatory Compliance (PRRC), and implement UDI/registration in EUDAMED.
Annex II technical documentation includes device description, label/IFU, design history, GSPR mapping, risk/benefit analysis, validation data, and versioning. Annex III requires a Post-Market Surveillance (PMS) plan and Post-Market Performance Follow-Up (PMPF), including periodic reports or PSURs.
Manufacturers must provide a matrix linking each applicable GSPR clause (Annex I) to supporting evidence—such as testing, standards used, and documentation references—to demonstrate compliance.
Unlike IVDD, IVDR mandates comprehensive performance evaluation data—scientific validity, analytical performance, and clinical performance—for all device risk classes, supported by clinical studies or literature when applicable.
IVDR requires structured PMS activities, including active data collection, complaint & vigilance handling, and for higher-risk devices (Class C/D), implementation of PMPF studies and regular PSUR submissions. A working, updated plan is mandatory.
Common compliance hurdles include insufficient risk and clinical evidence, incomplete GSPR mapping, lack of traceability in annexII documents, underdeveloped PMS/PMPF processes, and delays in Notified Body engagement.